Blood thinner study for safety in Chinese patients
Part of Blood & lymphatic, Heart & circulation clinical trials.
This study looks at how well certain blood thinners (NOACs and ticagrelor) work in Chinese patients and how they might affect bleeding risk. Researchers will measure drug levels and markers in your blood to try to make these medicines safer and more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older and of Chinese descent.
- Have a condition needing a NOAC (a type of blood thinner) for atrial fibrillation, blood clots, or after joint replacement surgery.
- Or have a recent acute coronary syndrome (a heart attack or severe chest pain) and be taking or starting ticagrelor.
- Not have taken the study medicine (NOAC or ticagrelor) in the past month, or be willing to participate if you've been on it for a week or more.
- Must not have HIV, hepatitis B or C, severe liver or kidney problems, active bleeding, or recent major surgery or bleeding events.
- Must not be taking certain medications that strongly interact with the study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two blood thinner medicines, edoxaban and rivaroxaban, in Chinese patients with a blood clot in a brain vein (cerebral venous thrombosis). It aims to see if these medicines are safe and work well.
This study examines new blood markers to predict blood clot and bleeding risks in patients with heart disease taking blood thinners. Understanding these markers may help doctors better predict complications and adjust treatment for individual patients.
This study is looking at how blood thinners work in Asian people with atrial fibrillation. It aims to better understand the balance between preventing strokes and the risk of bleeding.
This trial tests personalized blood thinner treatment for people who need long-term anticoagulation for conditions like atrial fibrillation or blood clots. The goal is to find the safest and most effective dose for each patient.
This trial is testing whether a newer type of blood thinner (called a NOAC) can be used safely right after a heart attack or related event, in addition to the standard two antiplatelet medicines. It focuses on patients who have higher risk signs, like elevated D-dimer levels or a higher PARIS risk score, to see if this approach is safe and effective at preventing future heart problems.
This study looks at how people doing well on certain blood thinners do when they have a stroke or bleeding while taking them. It will measure medication levels in your blood to understand stroke severity and recovery in the short and long term.
Hear when a new Rivaroxaban trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.